Deep product portfolio for anti-PD-1 immunotherapies
As we described in last week’s issue there is no doubt that agents that target the PD-1 pathway have generated much excitement among investors. There are several candidate drugs in late-stage development as anti-PD-1 immunotherapies targeting various solid cancers such as melanoma. In addition to the pharma players in this space, a number of biotech companies are focusing on this pathway. Many of their compounds are still at the early discovery and preclinical stages, but they are already showing potential.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter